Impact of hepatitis B immunization, Europe and worldwide

Journal of Hepatology

Volumn 39, Issue SUPPL. 1, 2003, Pages

  Namgyal, Pem ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INACTIVATED VACCINE; RECOMBINANT HEPATITIS B VACCINE;

CHINA; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DISEASE TRANSMISSION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG USE; ENDEMIC DISEASE; EUROPE; FINANCIAL MANAGEMENT; GAMBIA; HEALTH PROGRAM; HEALTH SERVICE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; INCIDENCE; INDONESIA; INFECTION PREVENTION; ITALY; LIVER CIRRHOSIS; MORTALITY; OCCUPATIONAL HAZARD; PREVALENCE; PRIORITY JOURNAL; SAUDI ARABIA; SEXUAL BEHAVIOR; SOUTH AFRICA; TAIWAN; THAILAND; UNITED STATES; VACCINATION; VIRUS INFECTION; WORLD HEALTH ORGANIZATION; YEAST;

EID: 0141860848     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(03)00269-1     Document Type: Conference Paper

References (39)

1. Kane MA. Global status of hepatitis B immunization. Lancet 1996;348:696.
2. Krugman S. The newly licensed hepatitis B vaccine. J Am Med Assoc 1982;247:2012-2015.
3. Valenzuela P, Medina A, Rutter WJ. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982;298:347-350.
4. McAleer W, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984;307:178-180.
5. Yeoh EK, Chang WK, Ip P, Chan KH, Chan E, Fung C. Efficacy and safety of recombinant hepatitis B vaccine in infants born to HBsAg-positive mothers. J Infect 1986;13(Suppl. A):15-18.
6. Stevens CE, Taylor PE, Tong MJ, Toy PT, Vyas GN, Nair PV, et al. Yeast-recombinant hepatitis B vaccine. J Am Med Assoc 1987;257:2612-2616.
7. Poovorawan Y, Sanpavat S, Pongpunlet W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. J Am Med Assoc 1989;261:3278-3281.
8. Andre FA, Zuckerman AJ. Review: protective efficacy of hepatitis B vaccine in neonates. J Med Virol 1994;44:144-151.
9. Ghendon Y. WHO strategy for the global elimination of new cases of hepatitis B. Vaccine 1990;8:S129-S133.
10. WHO. WHO Weekly Epidemiological Record, 1992;3:11-15.
11. WHO. Forty-fifth World Health Assembly. Resolution No. WHA45.17, 1992.
12. Kane MA. Status of hepatitis B immunization programs in 1998. Vaccine 1998;16:S104-S108.
13. WHO. Vaccines and Biologicals Annual Report 2000. WHO/V&B/01.01; 28-31.
14. GAVI. Report of the Second Board Meeting, Davos, Switzerland, 31 January 2000; GAVI/00.01.
15. GAVI. Meeting of the Proto-Board, Seattle, Washington, 12-13 July, 1999. GAVI/99.01.
16. Da Villa G. Rationale for infant and adolescent vaccination programs in Italy. Vaccine 2000;18:S31-S34.
17. Bonanni P, Colombai R, Gasparini R, Nostro AL, Tiscione E, Tomei A, et al. Impact of routine infant and adolescent hepatitis B vaccination in Tuscany, Central Italy. Pediatr Infect Dis J 1999;18:677-682.
18. Da Villa D, Piccinino F, Scolastico C, Fusco M, Piccininoo R, Sepe A. Long-term epidemiological survey of hepatitis B virus infection in a hyperendemic area (Afragola, southern Italy): results of a pilot vaccination project. Res Virol 1998;149:263-270.
19. Gatcheva N, Vladimirova N, Kourtchatova A. Implementing universal vaccination programs: Bulgaria. Vaccine 1995;13:S82-S83.
20. Chen HL, Chang MW, Ni YH, Hsu HY, Lee PI, Lee CY, et al. Seroepidemiology of hepatitis B virus infection in children-10 years of mass vaccination in Taiwan. J Am Med Assoc 1996;276:906-908.
21. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997;336:1855-1859.
22. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescent in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800.
23. Harpaz R, McMohan BJ. Elimination of new chronic hepatitis B virus infections: results of the Alaska immunization. J Infect Dis 2000;181:413-418.
24. Poovorawan Y, Theamboonlers A, Vimolket T, Sinlaparatsamee S, Chaiear K, Siraprapasiri T, et al. Impact of hepatitis B immunization as part of EPI. Vaccine 2001;19:943-949.
25. Chotard J, Inskip HM, Hall AJ, Loik F, Mendy M, Whittle H, et al. The Gambian hepatitis intervention study: follow-up of a cohort of children vaccinated against hepatitis B. J Infect Dis 1992;166:764-768.
26. Al-Faleh FZ, Al-Jeffri M, Ramai S, Al-Rashed R, Arif M, Rezeig M, et al. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after mass hepatitis B vaccination program. J Infect 1999;38:167-170.
27. UNICEF. GAVI Vaccine & Immunization Products Guideline for countries eligible for support from the global fund for children's vaccines. October 2000.
28. Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, et al. The hanging epidemiology of hepatitis B in the United States, need for alternative vaccination strategies. J Am Med Assoc 1990;263:1218-1222.
29. Armstrong GL, Mast EE, Wojcznski M, Margolis HS. Childhood hepatitis B virus infection in the United States before hepatitis B vaccination. Pediatrics 2001;108:1123-1128.
30. Tsebe JV, Burnett RJ, Hlungwani NP, Sibara MM, Venter PA, Mphahlele MJ. The first 5 years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 2001;19:3919-3926.
31. Xu ZY, Cao CB, Liu SS, et al. Control of hepatitis B in China. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, et al., editors. Viral hepatitis and liver disease. Turin, Italy: Edizioni Minerva Medica; 1997. p. 689-690.
32. Mahoney FJ, Woodruff B, Auerbach S, et al. Progress on the elimination of hepatitis B virus transmission in Micronesia and American Samoa. Pacific Health Dialog 1996;3:140-146.
33. Viviani S, Jack A, Hall AJ, Maine N, Mendy M, Montesano R, Whittle HC. Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine 1999;17:2946-2950.
34. Ruff TA, Gertig DM, Otto BF, Gust ID, Sutanto A, Soewarso TI, et al. Lombock hepatitis B model immunization project: toward universal infant hepatitis B immunization in Indonesia. J Infect Dis 1995;171:290-296.
35. Moulia-Pelat JP, Spiegel A, Martin PM, Cardines R, Boutin JP, Roux JF, et al. A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years. Vaccine 1994;12:499-502.
36. Mahoney F, Woodruff BA, Erben JJ, Coleman PJ, Reid EC, Schatz GC, et al. Evaluation of a hepatitis B vaccination on the prevalence of chronic HBV infection. J Infect Dis 1993;167:203-207.
37. Shih HH, Chang MH, Hsu HY, Lee PI, Ni YH, Chen DS. Long term immune response of universal hepatitis B vaccination in infancy: a community-based study in Taiwan. Pediatr Infect Dis J 1999;18:427-432.
38. Hsu HM, Lu CF, Lee SC, Lin SR, Chen DS. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass vaccination. J Infect Dis 1999;179:367-370.
39. Chunsuttiwat S, Biggs BA, Maynard J, Thamapalo S, Laoboripat S, Bovornsin S, et al. Integration of hepatitis B vaccination into the expanded program on immunizatiori in Chonburi and Chiangmai provinces, Thailand. Vaccine 1997;15:769-774.